UroGen Pharma Quote - URGN

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

10.71

Bid

10.03

Offer

11.20

Volume

0.00 Day's Range 0.00

9.78 52 Week Range 20.70

Market Cap

451.956M

Previous Close

10.71

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

370,053

Shares Outstanding

42,199,414

Dividend Yield

PE Ratio

-4.42

Earnings Per Share (EPS)

-2.42

Revenue

82.71M

Net Profit

-102.24M

UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment opt... UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.urogen.com

Headquarters

Ra'anana, Center, Isr

Founded

UroGen Pharma Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker URGN. The last closing price for UroGen Pharma was US$10.71. Over the last year, UroGen Pharma shares have traded in a share price range of US$ 9.78 to US$ 20.70.

UroGen Pharma currently has 42,199,414 shares in issue. The market capitalisation of UroGen Pharma is US$451.96 million. UroGen Pharma has a price to earnings ratio (PE ratio) of -4.42.

Form 8-K - Current report

UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations

- ICVB-1042 is an Oncolytic Virus Engineered to Selectively Destroy Cancer Cells While Retaining Potency and Trigger a Robust Immune Response...

UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102

Results presented at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU 2025) Treatment with UGN-102 resulted...

Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and...

Form 4 - Statement of changes in beneficial ownership of securities

UroGen Pharma to Present at Upcoming Investor Conferences

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...

New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)

-No RFS difference based on use of JELMYTO for primary chemoablation versus post-endoscopic ablation as adjuvant therapy -No RFS difference based...

ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025

ENVISION Reports 79.6% Complete Response Rate at 3 Months, 82.3% Duration of Response at 12 Months, and Consistent Safety Profile UroGen Pharma...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.11	1.03773584906	10.6	11.09	10.485	218272	10.71891313	CS
4	0.53	5.20628683694	10.18	11.87	9.86	281839	10.82755064	CS
12	-1.69	-13.6290322581	12.4	13.1332	9.78	370053	10.98495486	CS
26	-4.32	-28.7425149701	15.03	15.89	9.78	492471	12.18143369	CS
52	-8.39	-43.9267015707	19.1	20.7	9.78	488888	14.01372856	CS
156	4.6	75.2864157119	6.11	24.13	4.85	314132	13.946091	CS
260	-19.29	-64.3	30	30.89	4.85	253241	15.38347543	CS

URGN - Frequently Asked Questions (FAQ)

What is the current UroGen Pharma share price?

The current share price of UroGen Pharma is US$ 10.71

How many UroGen Pharma shares are in issue?

UroGen Pharma has 42,199,414 shares in issue

What is the market cap of UroGen Pharma?

The market capitalisation of UroGen Pharma is USD 451.96M

What is the 1 year trading range for UroGen Pharma share price?

UroGen Pharma has traded in the range of US$ 9.78 to US$ 20.70 during the past year

What is the PE ratio of UroGen Pharma?

The price to earnings ratio of UroGen Pharma is -4.42

What is the cash to sales ratio of UroGen Pharma?

The cash to sales ratio of UroGen Pharma is 5.46

What is the reporting currency for UroGen Pharma?

UroGen Pharma reports financial results in USD

What is the latest annual turnover for UroGen Pharma?

The latest annual turnover of UroGen Pharma is USD 82.71M

What is the latest annual profit for UroGen Pharma?

The latest annual profit of UroGen Pharma is USD -102.24M

What is the registered address of UroGen Pharma?

The registered address for UroGen Pharma is 9 HATAASIYA ST, PO BOX 2397, RA'ANANA, CENTER, 4365007

What is the UroGen Pharma website address?

The website address for UroGen Pharma is www.urogen.com

Which industry sector does UroGen Pharma operate in?

UroGen Pharma operates in the PHARMACEUTICAL PREPARATIONS sector

Symbol	Price	Vol.
MLGOMicroAlgo Inc	US$ 3.145 (173.48%)	30.94M
NAASNaaS Technology Inc	US$ 2.44 (75.54%)	12.27M
EDRYEuroDry Ltd	US$ 17.15 (59.91%)	10
FBRXForte Biosciences Inc	US$ 17.09 (59.72%)	2
FSEAFirst Seacoast Bancorp Inc	US$ 17.25 (57.68%)	6
DOYUDouYu International Holdings Ltd	US$ 6.73 (-58.17%)	22.19k
ISPOInspirato Inc	US$ 2.10 (-54.35%)	202
LBTYKLiberty Global Ltd	US$ 6.01 (-49.41%)	3
DFGXDimensional Global ex US Core Fixed Income ETF	US$ 30.01 (-42.73%)	1
ASRVAmeriServ Financial Inc	US$ 1.51 (-42.59%)	1
UPCUniverse Pharmaceuticals Inc	US$ 0.2245 (57.54%)	52.82M
MLGOMicroAlgo Inc	US$ 3.145 (173.48%)	30.94M
LICNLichen China Limited	US$ 0.0718 (2.43%)	18.31M
ADTXAditxt Inc	US$ 0.125 (5.22%)	16.8M
NAASNaaS Technology Inc	US$ 2.44 (75.54%)	12.27M

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

UroGen Pharma Ltd (URGN) Share Price

UroGen Pharma Ltd (URGN)

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

About UroGen Pharma Ltd

Ask ADVFN Intelligence (AI)

URGN Latest News

Form 8-K - Current report

UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations

UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102

Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

UroGen Pharma to Present at Upcoming Investor Conferences

New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)

ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025

Form 8-K - Current report

UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations

UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102

Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

UroGen Pharma to Present at Upcoming Investor Conferences

New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)

ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025

Form 8-K - Current report

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

URGN - Frequently Asked Questions (FAQ)

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

Go Ad-Free